IGC
IGC Pharma·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Consensus Rating "Strong Buy"
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IGC
Igc Pharma, Inc.
A biotech company that develops and commercializes cannabis-based therapies for various medical conditions
10224 Falls Road, Potomac, Maryland 20854
--
IGC Pharma, Inc., a Maryland corporation, was established on April 29, 2005. The company operates through two divisions, infrastructure and life sciences. The infrastructure sector, based in India, involves the execution of construction projects, the purchase and resale of physical commodities for infrastructure, and the leasing of heavy construction equipment. The life sciences division, formerly known as the plant and cannabinoid business, is headquartered in the United States and Colombia in South America. It includes a biotechnology component, as well as a vertically integrated cannabinoid-based healthcare and wellness business.
Company Financials
EPS
IGC has released its 2026 Q1 earnings. EPS was reported at -0.02, versus the expected -0.03, beating expectations. The chart below visualizes how IGC has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
IGC has released its 2026 Q1 earnings report, with revenue of 328.00K, reflecting a YoY change of 20.59%, and net profit of -1.60M, showing a YoY change of 32.76%. The Sankey diagram below clearly presents IGC's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
